Biotech M&A Happenings - Roche Acquires Telavant for $7.1B; Bristol Acquires Mirati for $4.8B

Week Ending October 20th, 2023

• Biotech: 5 Transactions (1 IPO, 3 Follow-Ons, and 1 PIPE) totaling just under $1 Billion

• Med Tech: No Current Week Transactions

2023 YTD

• 145Biotech transactions totaling just under $22 Billion v. 2022: 125 Biotech transactions totaling just under $16 Billion

• 16 Med Tech transactions totaling just over $1 Billion v. 2022: 10 Med Tech transactions just under $900 Million

Private Transactions:

• Biotech: 196Transactions / 57 European Transactions

• Med Tech: 108 US Transactions / 35 European Transactions

October Major Transactions:

• Roche aqcuired Telavant - $7.1B

• Bristol Myers Squibb aquired Mirati Therapeutics - $4.8B; $58/Share

• AbbVie acquired Mitokinin - $110M

• Kyowa Kirin acquired Orchard Therapeutics - $387M; $16/Share

• Eli Lilly acquired Point Biopharma - $1.4B; $12.50/Share

September Major Transactions:

• Alfasigma acquired Intercept Pharmaceuticals - $794M; $19/Share

August Major Transactions:

• Otsuka Pharmaceutical acquired Mindset Pharma - $59M; $0.75/Share

• Harmony Biosciences acquired Zynerba Pharmaceuticals - $60M; $1.11/Share

• Regeneron acquired Decibel Therapeutics - $107M; $4/Share